Scandion Oncology Financials
| SCOL Stock | SEK 0.06 0 4.62% |
Scandion |
Please note, the imprecision that can be found in Scandion Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Scandion Oncology AS. Check Scandion Oncology's Beneish M Score to see the likelihood of Scandion Oncology's management manipulating its earnings.
Scandion Oncology Stock Summary
Scandion Oncology competes with ExpreS2ion Biotech, Hansa Biopharma, Fluoguide, Saniona AB, and Oncopeptides. Scandion Oncology AS, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. The company was founded in 2017 and is based in Copenhagen, Denmark. Scandion Oncology operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | DK0061031895 |
| Business Address | Symbion, Copenhagen, Denmark, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.scandiononcology.com |
| Phone | 45 38 10 20 17 |
| Currency | SEK - Swedish Kronor |
You should never invest in Scandion Oncology without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Scandion Stock, because this is throwing your money away. Analyzing the key information contained in Scandion Oncology's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Scandion Oncology Key Financial Ratios
Scandion Oncology's financial ratios allow both analysts and investors to convert raw data from Scandion Oncology's financial statements into concise, actionable information that can be used to evaluate the performance of Scandion Oncology over time and compare it to other companies across industries.Scandion Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Scandion Oncology's current stock value. Our valuation model uses many indicators to compare Scandion Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Scandion Oncology competition to find correlations between indicators driving Scandion Oncology's intrinsic value. More Info.Scandion Oncology AS is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Scandion Oncology's earnings, one of the primary drivers of an investment's value.Scandion Oncology Systematic Risk
Scandion Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Scandion Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Scandion Oncology correlated with the market. If Beta is less than 0 Scandion Oncology generally moves in the opposite direction as compared to the market. If Scandion Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Scandion Oncology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Scandion Oncology is generally in the same direction as the market. If Beta > 1 Scandion Oncology moves generally in the same direction as, but more than the movement of the benchmark.
Scandion Oncology January 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Scandion Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Scandion Oncology AS. We use our internally-developed statistical techniques to arrive at the intrinsic value of Scandion Oncology AS based on widely used predictive technical indicators. In general, we focus on analyzing Scandion Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Scandion Oncology's daily price indicators and compare them against related drivers.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 25.0 | |||
| Value At Risk | (9.38) | |||
| Potential Upside | 6.29 |
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.